Rallybio (RLYB) Long-Term Investments (2020 - 2025)
Rallybio (RLYB) posted Long-Term Investments of $626000.0 for Q2 2025, up 51.57% sequentially from $413000.0 in Q1 2025, and up 10.21% YoY from $568000.0 in Q2 2024.
Rallybio (RLYB) Long-Term Investments (2020 - 2025) Analysis & Trends
Rallybio has reported Long-Term Investments for 6 years, with the latest figure at $626000.0 in Q2 2025.
- Quarterly Long-Term Investments rose 10.21% year-over-year to $626000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $626000.0 (up 10.21% YoY) and the FY2023 annual result came in at $239000.0, up 696.67% from the prior year.
- Long-Term Investments climbed to $626000.0 in Q2 2025 per RLYB's latest filing, from $413000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $1.4 million in Q2 2021 and troughed at $30000.0 in Q4 2022.
- A 5-year average of $467266.7 and a median of $413000.0 in 2025 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments sank 96.27% in 2022, then soared 696.67% in 2023.
- Over 5 years, Long-Term Investments stood at $805000.0 in 2021, then tumbled by 96.27% to $30000.0 in 2022, then jumped by 696.67% to $239000.0 in 2023, then surged by 80.33% to $431000.0 in 2024, then jumped by 45.24% to $626000.0 in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $626000.0, $413000.0, and $431000.0 for Q2 2025, Q1 2025, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 626,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Sep 30, 2024 | 431,000.00 |
| Jun 30, 2024 | 568,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Dec 31, 2023 | 239,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Mar 31, 2023 | 217,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 244,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 415,000.00 |
| Dec 31, 2021 | 805,000.00 |
| Sep 30, 2021 | 1.03 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Dec 31, 2020 | 310,000.00 |